Study

Interventions

Patients

Overall survival

PSA 50% decline

Time To Progression

Subsection 1.

Estramustine vs BSC or Hormones

Iversen 1997

1. Estramustine plus standard therapy

61

median 9.4 mths

37%

median 4.6 months

2. Placebo plus standard therapy.

68

5.0

2%

5.0

De Kernion 1988

1. Estramustine

109

not reported

not reported

not reported

2. Flutamide

111

Johanssen 1991

1. Estramustine

52

8.3

not reported

2.4

2. Medroxyprogesterone acetate

53

11.6

3.0

Murphy 1977

1. Estramustine

46

data not extractable

not reported

11.3 (mean)

2. Streptozotocin

38

8.0

3. Standard therapy

21

7.5

Subsection 2.

Estramustine versus Single Cytotoxic

Elomaa 1991

1. Estramustine

20

15.0

not reported

13.0

2. Epirubicin low‐dose

21

15.0

12.0

Newling 1993

1. Estramustine

82

10.0

not reported

5.0

2. Mitomycin C

79

10.0

5.0

Loening 1983

1. Estramustine

63

10.8

not reported

66% at 12 weeks

2. Methotrexate

67

11.5

59%

3. Cisplatin

59

10.0

64%

Anderstrom 1995

1. Estramustine

74

9.5

not reported

4.4

2. MPA + Epirubicin

75

11.5

7.7

Tveter 1990

1. Estramustine

25

not reported

not reported

2.0

2. Epirubicin+medroxyprogesterone acetate

24

5.0

3. Epirubicin + placebo

30

3.0

Subsection 3.

Estramustine versus Estra + Cytotoxic

Albrecht 2004

1. Estramustine

45

12.7

28.9%

6.8

2. Estramustine + vinblastine

45

11.0

24.6%

7.7

Hudes 1999

1. Estramustine + vinblastine (VinB)

100

11.9

25*

3.7*

2. Vinblastine

101

9.2

3.0

2.2

Soloway 1981

1. Estramustine

38

mean 8.9

not reported

not reported

2. Vincristine

42

9.1

3. Estramustine + Vincristine

41

7.9

Soloway 1983

1. Estramustine

50

5.2

not reported

82%

2. Cisplatin

51

7.0

67%

3. Estramustine + Cisplatin

48

7.0

79%

Berry 2004

1. Estramustine + Paclitaxel

79

16.1*

47%

5.5

2. Paclitaxel

84

13.1

27%

4.3

Galsky 2005

1. Estramustine + ixabepilone

45

not reported

69%

5.2

2. Ixabepilone

47

48%

4.4

Murphy 1979

1. Estramustine + Prednimustine

54

12.3

not reported

not reported

2. Prednimustine

62

12.0

Subsection 4.

Complex Combinations with Estarmustine

Dimopoulos 2004

1. Estramustine + Etoposide

20

18.8

60%

6.0

2. Lanreotide+Cisplatin+Dexamethasone

18

18.0

66%

4.0

Akaza 1988

1. Estramustine+peplomycin (peplo)

22

5.5

not reported

not reported

2. Estramustine+peplo+doxorubicin (Dox)

22

7.5

Millikan 2003

1. Estr/VinB alternating ketoconazole/Dox

37

23.5

56%

data not extractable

2. Estra/paclitaxel/etoposide

38

17.0

41%

* Statistically significant P < 0.05

Study

Interventions

Patients

Median Survival

PSA Response %

Progression ‐ median

Scott 1976

1. Cyclophosphamide (CycloP)

41

data not reported

data not reported

53%

2. 5‐Fluorouracil (5FU)

33

63%

3. Standard therapy

36

81%

Chlebrowski 1978

1. CycloP

15

7.2 months

data not reported

12.7 months

2. CycloP + 5FU + Doxorubicin (Dox)

12

8.9

5.9

Loening 1981

1. CycloP

47

10.5

data not reported

4.8

2. Methyl ‐ CCNU

38

5.2

3.8

3. Hydroxyurea (HU)

40

4.8

4.8

Muss 1981

1. CycloP

21

9.3

data not reported

4.5

2. CycloP + Methotrexate (MTX) +5FU

19

7.1

4.5

Kasimis 1986

1. CycloP

16

data not reported

data not reported

1.2*

2. 5FU + Dox + Mitomycin C (MMC)

15

4.0

Saxman 1992

1. CycloP

53

6.5

data not reported

4.2*

2. CycloP + Dox + MTX

50

8.1

data not reported

6.2

Page 1985

1. CycloP + 5FU

27

5.8

data not reported

data not reported

2. Dox + Lomustine

24

9.8

Murphy 1988

1. CycloP + Dox

60

10.6

data not reported

5.3

2. MTX

63

10.6

5.0

3. CycloP + Cisplatin + 5FU

57

10.6

4.1

Herr 1982

1. CycloP + MTX + 5FU

20

6.5

data not reported

65%

2. Chloroethyl‐CCNU

20

6.0

70%

Graham 1986

1. CycloP+MTX+5FU+prednisone (Pred)

39

9.9

data not reported

data not reported

2. MTX+5FU+Pred+Vincristine+melphalan

19

13.8

Study

Interventions

Patients

Median Survival

PSA Response

Progression ‐ Median

Smalley 1981

1. 5‐Fluorouracil (5FU)

32

8.8

not reported

not reported

2. 5‐FU+cyclophosphamide+doxorubicin

39

6.5

Daliani 1995

1. 5‐FU

23

8.25

12%

not reported

2. 5‐FU + interferon alpha

28

8.25

17%

Beul 1997

1. 5‐FU

25

6.9

33

3.7

2. 5‐FU + Folinic acid

25

4.8

20

4.0

Droz 2003

1. Oxaliplatin

26

9.4

18

2.6

2. Oxaliplatin + 5‐FU

28

11.4

19

3.4

Study

Interventions

Patients

Median Overall Surv

% PSA Response

Disease Progression

Torti 1985

1. Doxorubicin (Dox)

20

12.1 months

Not reported

4.2 median months

2. Dox + Cisplatin

17

10.8

6.3

Francini 1993

1. Dox

24

8.0

Not reported

Not reported

2. Epirubicin

48

12.5

Leaf 2003

1. Dox

76

7.5

Not reported

2.6

2. Dox + Diethylstilbestrol

74

9.1

3.2

Rangel 1992

1.Dox + prednisone

59

11.8

Not reported

3.8

2. Prednisone

51

10.0

2.3

Milikan 2001

1. Dox + ketoconazole

44

12.5

50%

3.3

2. Ketoconazole

45

12.5

40%

3.3

Laurie 1992

1.fluorouracil+Dox+mitomycin

70

8.7

Not reported

Not reported

2. mitomycin‐Dox‐fluorouracil

72

7.1

Study

Interventions

Patients

Median Survival

PSA response %

Progression (median)

Kantoff 1999

1. Mitoxantrone+hydrocortisone

110

12.3 months

19

3.7 months

2. Hydrocortisone

123

12.6

14

2.3

Tannock 1996

1. Mitoxantrone+Prednisone

80

12

31

Not reported

2. Prednisone

81

12

22

Berry 2002

1. Mitoxantrone+Prednisone

56

23

48

8.1

2. Prednisone

63

19

24

4.1

Study

Interventions

Patients

Median Survival

% PSA Response

Progression (median)

Dahut 2004

1.Docetaxel (Doc)

25

14.7 months

37

3.7

2. Doc + Thalidomide

50

28.9

53

5.9

Oudart 2005

1. Doc(70mg)+Estramustine+Prednisone

44

18.6

67*

8.8*

2.Doc(35mg)+Estramustine+Prednisone

44

18.4

63*

9.3*

3. Mitoxantrone + Prednisone

42

13.4

18

17.0

Tannock 2004

1. Doc (3‐weekly)+Prednisone

335

18.9*

45*

38

2. Doc (weekly) + Prednisone

334

17.4

48*

35

3. Mitoxantrone +Prednisone

337

16.5

32

56

Petrylak 2004

1. Doc + Estramustine

386

17.5

50

6.3

2. Mitoxantrone + Prednisone

384

15.6*

27*

3.2*

* sigificantly different p <0.05